🇺🇸 FDA
Patent

US 9278091

Compounds for the treatment of Clostridium difficile associated disease

granted A61KA61K31/4164A61K31/424

Quick answer

US patent 9278091 (Compounds for the treatment of Clostridium difficile associated disease) held by SUMMIT THERAPEUTICS PLC expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SUMMIT THERAPEUTICS PLC
Grant date
Tue Mar 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K31/4164, A61K31/424, A61K31/4365, A61K31/437